肝硬化肌少症的发病机制与诊疗现状

刘钰懿; 陈东风; 颜綦先

doi:10.3969/j.issn.1001-5256.2022.01.033

肝硬化肌少症的发病机制与诊疗现状

DOI: 10.3969/j.issn.1001-5256.2022.01.033

陆军特色医学中心(大坪医院) 消化内科，重庆 400042

基金项目:

国家自然科学基金 (81972305)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：刘钰懿、陈东风负责调研整理文献，设计论文框架，撰写论文; 颜綦先负责终审论文。

详细信息

通信作者:
颜綦先，402010444@qq.com

计量
- 文章访问数: 786
- HTML全文浏览量: 152
- PDF下载量: 129
- 被引次数: 0
出版历程
- 收稿日期: 2021-06-10
- 录用日期: 2021-07-30
- 出版日期: 2022-01-20

Current status of the pathogenesis, diagnosis, and treatment of sarcopenia in patients with liver cirrhosis

Department of Gastroenterology, Army Medical Center of PLA & Daping Hospital, Chongqing 400042, China

Research funding:

National Natural Science Foundation of China (81972305)

摘要

摘要: 肌少症是肝硬化患者常见的并发症，发病率高达40%~70%，增加肝硬化患者并发症的发生，严重影响患者的生活质量和生存期。肝硬化肌少症发病机制复杂，临床表现易被忽略，诊断标准尚未达成共识，针对性治疗药物较少，亟待临床医生高度重视，并加强其发病机制的研究和治疗药物的研发。
- 肝硬化 /
- 肌少症 /
- 治疗学
Abstract: Sarcopenia is a common complication in patients with liver cirrhosis, with an incidence rate of up to 40%-70%, which increases the incidence rate of complications in patients with liver cirrhosis and seriously affects patients' quality of life and survival time. Sarcopenia in liver cirrhosis has a complex pathogenesis, and its clinical manifestations are easily ignored. No consensus has been reached on diagnostic criteria, and there are few targeted therapeutic drugs. Therefore, it should be taken seriously by clinician and the research on pathogenesis and therapeutic drugs should be strengthened.
- Liver Cirrhosis /
- Sarcopenia /
- Therapeutics

HTML全文

参考文献(45)

[1]	TANDON P, NEY M, IRWIN I, et al. Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value[J]. Liver Transpl, 2012, 18(10): 1209-1216. DOI: 10.1002/lt.23495.
[2]	ROSENBERG IH. Sarcopenia: Origins and clinical relevance[J]. Clin Geriatr Med, 2011, 27(3): 337-339. DOI: 10.1016/j.cger.2011.03.003.
[3]	CRUZ-JENTOFT AJ, BAEYENS JP, BAUER JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People[J]. Age Ageing, 2010, 39(4): 412-423. DOI: 10.1093/ageing/afq034.
[4]	PENG S, PLANK LD, MCCALL JL, et al. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: A comprehensive study[J]. Am J Clin Nutr, 2007, 85(5): 1257-1266. DOI: 10.1093/ajcn/85.5.1257.
[5]	HAO RR, WANG H, WANG HY, et al. Analysis of risk factors for senile sarcopenia and its relationship with NAFLD[J]. J Clin Exp Med, 2020, 319(15): 1588-1591. DOI: 10.3969/j.issn.1671-4695.2020.15.006. 郝瑞瑞, 王欢, 王海燕, 等. 老年肌少症的危险因素分析及与NAFLD的关系研究[J]. 临床和实验医学杂志, 2020, 319(15): 1588-1591. DOI: 10.3969/j.issn.1671-4695.2020.15.006.
[6]	KIM G, KANG SH, KIM MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(10): e0186990. DOI: 10.1371/journal.pone.0186990.
[7]	NISHIKAWA H, ENOMOTO H, ISHⅡ A, et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis[J]. J Cachexia Sarcopenia Muscle, 2017, 8(6): 915-925. DOI: 10.1002/jcsm.12212.
[8]	LEE JH, JUN HS. Role of myokines in regulating skeletal muscle mass and function[J]. Front Physiol, 2019, 10: 42. DOI: 10.3389/fphys.2019.00042.
[9]	WING SS, LECKER SH, JAGOE RT. Proteolysis in illness-associated skeletal muscle atrophy: From pathways to networks[J]. Crit Rev Clin Lab Sci, 2011, 48(2): 49-70. DOI: 10.3109/10408363.2011.586171.
[10]	YANG QQ, SUN Y. Research progress on molecular mechanism of skeletal muscle mass reduction in sarcopenia[J]. J Clin Exp Med, 2020, 313(9): 1006-1009. DOI: 10.3969/j.issn.1671-4695.2020.09.032. 杨琦琦, 孙颖. 肌少症中骨骼肌质量减少的分子机制研究进展[J]. 临床和实验医学杂志, 2020, 313(9): 1006-1009. DOI: 10.3969/j.issn.1671-4695.2020.09.032.
[11]	EGERMAN MA, GLASS DJ. Signaling pathways controlling skeletal muscle mass[J]. Crit Rev Biochem Mol Biol, 2014, 49(1): 59-68. DOI: 10.3109/10409238.2013.857291.
[12]	HAN HQ, MITCH WE. Targeting the myostatin signaling pathway to treat muscle wasting diseases[J]. Curr Opin Support Palliat Care, 2011, 5(4): 334-341. DOI: 10.1097/SPC.0b013e32834bddf9.
[13]	SCHIAFFINO S, DYAR KA, CICILIOT S, et al. Mechanisms regulating skeletal muscle growth and atrophy[J]. FEBS J, 2013, 280(17): 4294-4314. DOI: 10.1111/febs.12253.
[14]	WANG Y, PESSIN JE. Mechanisms for fiber-type specificity of skeletal muscle atrophy[J]. Curr Opin Clin Nutr Metab Care, 2013, 16(3): 243-250. DOI: 10.1097/MCO.0b013e328360272d.
[15]	LEE K, OCHI E, SONG H, et al. Activation of AMP-activated protein kinase induce expression of FoxO1, FoxO3a, and myostatin after exercise-induced muscle damage[J]. Biochem Biophys Res Commun, 2015, 466(3): 289-294. DOI: 10.1016/j.bbrc.2015.08.126.
[16]	GLASS C, HIPSKIND P, TSIEN C, et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: A prospective controlled study[J]. J Appl Physiol (1985), 2013, 114(5): 559-565. DOI: 10.1152/japplphysiol.01042.2012.
[17]	BHANJI RA, MOCTEZUMA-VELAZQUEZ C, DUARTE-ROJO A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis[J]. Hepatol Int, 2018, 12(4): 377-386. DOI: 10.1007/s12072-018-9875-9.
[18]	DASARATHY S, HATZOGLOU M. Hyperammonemia and proteostasis in cirrhosis[J]. Curr Opin Clin Nutr Metab Care, 2018, 21(1): 30-36. DOI: 10.1097/MCO.0000000000000426.
[19]	DAVULURI G, ALLAWY A, THAPALIYA S, et al. Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress[J]. J Physiol, 2016, 594(24): 7341-7360. DOI: 10.1113/JP272796.
[20]	DAM G, OTT P, AAGAARD NK, et al. Branched-chain amino acids and muscle ammonia detoxification in cirrhosis[J]. Metab Brain Dis, 2013, 28(2): 217-220. DOI: 10.1007/s11011-013-9377-3.
[21]	QIU J, THAPALIYA S, RUNKANA A, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism[J]. Proc Natl Acad Sci U S A, 2013, 110(45): 18162-18167. DOI: 10.1073/pnas.1317049110.
[22]	ÁBRIGO J, ELORZA AA, RIEDEL CA, et al. Role of oxidative stress as key regulator of muscle wasting during cachexia[J]. Oxid Med Cell Longev, 2018, 2018: 2063179. DOI: 10.1155/2018/2063179.
[23]	DAVULURI G, KROKOWSKI D, GUAN BJ, et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis[J]. J Hepatol, 2016, 65(5): 929-937. DOI: 10.1016/j.jhep.2016.06.004.
[24]	NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
[25]	DASARATHY J, ALKHOURI N, DASARATHY S. Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: A critical review of literature[J]. Liver Int, 2011, 31(9): 1250-1258. DOI: 10.1111/j.1478-3231.2011.02498.x.
[26]	PONZIANI FR, GASBARRINI A. Sarcopenia in patients with advanced liver disease[J]. Curr Protein Pept Sci, 2018, 19(7): 681-691. DOI: 10.2174/1389203718666170428121647.
[27]	MONTANO-LOZA AJ, DUARTE-ROJO A, MEZA-JUNCO J, et al. Inclusion of Sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2015, 6(7): e102. DOI: 10.1038/ctg.2015.31.
[28]	HAN E, LEE YH, KIM BK, et al. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2018, 48(3): 300-312. DOI: 10.1111/apt.14843.
[29]	CAREY EJ, LAI JC, WANG CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017, 23(5): 625-633. DOI: 10.1002/lt.24750.
[30]	WELLS CI, MCCALL JL, PLANK LD. Relationship between total body protein and cross-sectional skeletal muscle area in liver cirrhosis is influenced by overhydration[J]. Liver Transpl, 2019, 25(1): 45-55. DOI: 10.1002/lt.25314.
[31]	DICHI JB, DICHI I, MAIO R, et al. Whole-body protein turnover in malnourished patients with child class B and C cirrhosis on diets low to high in protein energy[J]. Nutrition, 2001, 17(3): 239-242. DOI: 10.1016/s0899-9007(00)00567-0.
[32]	CHEN XM, WANG Q, CHENG DL, et al. Correlation analysis of sarcopenia and hepatic encephalopathy in patients with hepatitis B cirrhosis[J]. Chin J Clin Nutr, 2021, 28(5): 290-296. DOI: 10.3760/cma.j.cn115822-20200902-00204. 陈晓明, 王乔, 成德雷, 等. 乙型肝炎病毒感染后肝硬化患者肌肉减少与肝性脑病的相关性分析[J]. 中华临床营养杂志, 2021, 28(5): 290-296. DOI: 10.3760/cma.j.cn115822-20200902-00204.
[33]	European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
[34]	AMODIO P, BEMEUR C, BUTTERWORTH R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus[J]. Hepatology, 2013, 58(1): 325-336. DOI: 10.1002/hep.26370.
[35]	KITAJIMA Y, TAKAHASHI H, AKIYAMA T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis[J]. J Gastroenterol, 2018, 53(3): 427-437. DOI: 10.1007/s00535-017-1370-x.
[36]	PLAUTH M, CABRé E, CAMPILLO B, et al. ESPEN guidelines on parenteral nutrition: Hepatology[J]. Clin Nutr, 2009, 28(4): 436-444. DOI: 10.1016/j.clnu.2009.04.019.
[37]	TSIEN C, DAVULURI G, SINGH D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis[J]. Hepatology, 2015, 61(6): 2018-2029. DOI: 10.1002/hep.27717.
[38]	MALAGUARNERA M, VACANTE M, GIORDANO M, et al. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: A randomized, double-blind, placebo-controlled study[J]. Am J Clin Nutr, 2011, 93(4): 799-808. DOI: 10.3945/ajcn.110.007393.
[39]	EBADI M, BHANJI RA, MAZURAK VC, et al. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2019, 49(2): 173-182. DOI: 10.1111/apt.15029.
[40]	KONSTANTAKIS C, TSELEKOUNI P, KALAFATELI M, et al. Vitamin D deficiency in patients with liver cirrhosis[J]. Ann Gastroenterol, 2016, 29(3): 297-306. DOI: 10.20524/aog.2016.0037.
[41]	BECKER C, LORD SR, STUDENSKI SA, et al. Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial[J]. Lancet Diabetes Endocrinol, 2015, 3(12): 948-957. DOI: 10.1016/S2213-8587(15)00298-3.
[42]	PICARDI A, de OLIVEIRA AC, MUGUERZA B, et al. Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis[J]. J Hepatol, 1997, 26(1): 191-202. DOI: 10.1016/s0168-8278(97)80026-8.
[43]	YURCI A, YUCESOY M, UNLUHIZARCI K, et al. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis[J]. Clin Res Hepatol Gastroenterol, 2011, 35(12): 845-854. DOI: 10.1016/j.clinre.2011.09.005.
[44]	DUARTE-ROJO A, RUIZ-MARGÁIN A, MONTAÑO-LOZA AJ, et al. Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list[J]. Liver Transpl, 2018, 24(1): 122-139. DOI: 10.1002/lt.24958.
[45]	TANDON P, ISMOND KP, RIESS K, et al. Exercise in cirrhosis: Translating evidence and experience to practice[J]. J Hepatol, 2018, 69(5): 1164-1177. DOI: 10.1016/j.jhep.2018.06.017.